By using the ex vivo rat tendon fascicle model and the in vivo rat rotator cuff tendinopathy model, we aimed to further elucidate the biological mechanisms of IL-17A blockade underlying the reported therapeutic effects in human early-stage tendinopathy. This evidence concerns the gene IL17A and disease of the tendon.